Pirbright Study Links COVID-19 Immunity to Bat Coronavirus Protection

Scientists at The Pirbright Institute and King’s College London have revealed that immunity generated by SARS-CoV-2 infection or vaccination may offer significant protection against a range of other bat coronaviruses. This discovery, published in two companion articles in PLOS Biology, suggests that the widespread exposure of the human population to SARS-CoV-2 has inadvertently raised the biological barrier for related viruses attempting to spill over from animal reservoirs. The research provides a critical new perspective on pandemic preparedness, indicating that the immune landscape shaped by the current pandemic could serve as a partial shield against future zoonotic threats from the sarbecovirus sub-group.

The study focused on sarbecoviruses, the specific sub-group of coronaviruses that includes both SARS-CoV-1 and SARS-CoV-2. Researchers examined how these viruses interact with angiotensin-converting enzyme 2, or ACE2, the cellular receptor that many coronaviruses utilize to enter host cells. By investigating the ability of various bat coronaviruses to use ACE2 proteins from a broad spectrum of species, the team aimed to understand the host range of these viruses. This host range is a key determinant of spillover risk, as viruses capable of infecting a wide variety of animals are generally considered more likely to jump to humans.

The team analyzed fifteen representative bat coronavirus spike proteins using libraries of ACE2 receptors derived from thirty-four different species. These species included humans, livestock, rodents, and animals previously proposed as intermediate hosts in the transmission chain. The analysis revealed a distinct pattern in receptor usage among the different evolutionary groups of bat sarbecoviruses. Specifically, the researchers identified so-called generalist sarbecoviruses, which can utilize ACE2 receptors from many different species, and found that these were largely confined to the same evolutionary lineage as SARS-CoV-2.

Dr. Nazia Thakur, a postdoctoral scientist at Pirbright and the lead author of the study, explained that the bat coronaviruses currently considered most likely to spill over into humans are also the most likely to be recognized by existing COVID-19 immunity. She noted that while the risk of spillover can never be entirely eliminated, the global exposure to SARS-CoV-2 may have created a more robust immune defense against related viruses. This finding implies that the immune systems of many people are already primed to recognize and neutralize potential future pathogens that share structural similarities with the virus that caused the current pandemic.

The research also highlighted the dynamic nature of viral evolution during the pandemic. The team investigated how the host range of SARS-CoV-2 itself has changed over time. They found that variants, particularly those within the Omicron lineage, acquired specific mutations in the receptor binding domain. These mutations resulted in shifting patterns of ACE2 usage across different animal species, demonstrating that the relationship between viral evolution and host susceptibility is not static but continuously evolving in response to immune pressure and environmental factors.

To assess the practical implications for human health, the scientists examined blood samples from individuals who had recovered from COVID-19. The antibodies present in these samples were tested against a range of bat coronaviruses to measure their neutralizing capacity. The results showed that these antibodies successfully neutralized a variety of closely related bat coronaviruses. This cross-neutralization indicates that the immune response triggered by SARS-CoV-2 is not strictly specific to that single virus but extends to a broader family of related pathogens, providing a layer of protection against potential new infections.

Professor Katie Doores of King’s College London emphasized that the viruses showing the strongest antigenic similarity to SARS-CoV-2 were the most readily recognized and neutralized by the antibodies generated following infection. In contrast, more distantly related bat coronaviruses tended to be specialists, capable of using ACE2 receptors from only a limited range of hosts. However, the researchers also detected lower levels of neutralization against these more distant viruses, suggesting that there is some degree of broader protection even against pathogens that are not closely related to SARS-CoV-2.

Further experiments conducted at both institutions identified several monoclonal antibodies capable of recognizing a remarkably diverse range of sarbecoviruses. The second companion article in the study detailed where these monoclonal antibodies bind on the viral surface, highlighting conserved regions of the coronavirus spike protein. These conserved regions are less likely to mutate without compromising the virus’s ability to infect cells, making them ideal targets for the development of next-generation vaccines and therapeutics. This approach could lead to the creation of pan-sarbecovirus vaccines that offer protection against multiple strains simultaneously.

Dr. Dalan Bailey, head of the Viral Glycoproteins group at Pirbright, described the evidence of cross-neutralization of even some distantly related bat coronaviruses as an encouraging finding. He suggested that this capability points toward the feasibility of developing broadly protective vaccines or therapeutics that can cover a wide spectrum of sarbecoviruses. By targeting conserved epitopes, such interventions could provide a more durable and comprehensive defense against future zoonotic spillover events, reducing the likelihood of a new pandemic emerging from the bat reservoir.

The work underscores the importance of understanding virus host range, receptor usage, and immune recognition in an integrated manner rather than in isolation. By identifying the specific characteristics that distinguish higher-risk viruses from those less likely to spill over into humans, researchers hope to strengthen global pandemic preparedness efforts. This study provides a scientific basis for monitoring specific bat coronavirus lineages and developing targeted interventions that leverage existing immunity to protect against future viral threats, ultimately contributing to a more resilient global health system.

Subject of Research: Cross-immunity between SARS-CoV-2 and bat sarbecoviruses via ACE2 receptor usage

Article Title: COVID-19 immunity may help protect against other bat coronaviruses

Article References: COVID-19 immunity may help protect against other bat coronaviruses. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: SARS-CoV-2, bat coronaviruses, ACE2 receptor, cross-immunity, spillover risk, Pirbright Institute, King's College London, pandemic preparedness, monoclonal antibodies, zoonotic diseases, COVID-19, immunity